Business Context and Reporting Period
Company: Innate Pharma SA
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Report Date: September 15, 2022
Reporting Period: The filing incorporates by reference the Half-Year Financial Report for the period January 1, 2022, to June 30, 2022 (Exhibit 99.2) and a press release dated September 15, 2022 (Exhibit 99.1).
Key Financial Metrics
The provided text serves as a cover sheet and incorporation by reference document. It does not contain the actual financial data tables or narrative from the Half-Year Financial Report.
- Revenue: Not provided in the filing text.
- Profit/Loss: Not provided in the filing text.
- Cash Flow: Not provided in the filing text.
- Margins: Not provided in the filing text.
- Debt and Liquidity: Not provided in the filing text.
Material Changes
The filing text does not provide specific comparative data or material changes versus the prior period. Investors must refer to the incorporated Exhibit 99.2 (H1 2022 Financial Report) for year-over-year analysis.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. These items are expected to be detailed within the incorporated press release (Exhibit 99.1) and financial report (Exhibit 99.2).
Investor Verification Checklist
- Review Exhibit 99.2 for the actual H1 2022 financial statements, including cash burn rate and liquidity position.
- Review Exhibit 99.1 for the press release details regarding clinical trial progress or commercial updates for the period ending June 30, 2022.
- Verify the incorporation by reference into the active registration statements (Form F-3 File No. 333-252074 and Form S-8 File No. 333-233865).
- Confirm the CEO signature and authorization by Mondher Mahjoubi.